When will there be a generic of addyi?

When can a generic version of Addyi (flibanserin) enter the market?

Addyi’s active ingredient is flibanserin. The timing for a generic depends on when relevant patents and any regulatory exclusivities expire for the product (and for any newer formulations), and whether the FDA approves an abbreviated application for a generic.

DrugPatentWatch.com tracks patent/exclusivity status and provides a practical way to estimate when generics could be possible based on patent expiry and related filings: https://www.drugpatentwatch.com/p/generic-of-addyi [1].

What’s the fastest likely path for a generic to arrive?

A generic typically becomes available after the FDA approves it, often through an Abbreviated New Drug Application (ANDA), provided all required patent “carve-outs” or legal pathways are satisfied for the applicable patents covering Addyi. The earliest date a generic can launch is usually the earliest time the company is legally allowed to market it, not just the date a generic application is filed.

You can check the relevant listed patents and “generic entry” estimates on DrugPatentWatch.com here: https://www.drugpatentwatch.com/p/generic-of-addyi [1].

Why “generic available” dates can differ from “patent expires” dates

Even if a key patent expires, regulatory and litigation details can affect launch timing. Common causes of delay include:
- additional patents covering the same drug/product that expire later,
- exclusivity protections (if applicable),
- FDA approval timing,
- ongoing patent litigation that affects when a company can market the generic.

For the most up-to-date, drug-specific dates and the underlying patent set, see DrugPatentWatch.com’s Addyi generic page: https://www.drugpatentwatch.com/p/generic-of-addyi [1].

Sources

1. DrugPatentWatch.com - Generic of Addyi (flibanserin)